Artal Group’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Artal Group’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-500,500	Closed	-$31K	–	148
2022 Q2	$31K	Hold	500,500	–	–	﹤0.01%	135
2022 Q1	$826K	Hold	500,500	–	–	0.03%	128
2021 Q4	$1.2M	Hold	500,500	–	–	0.03%	138
2021 Q3	$2.73M	Hold	500,500	–	–	0.06%	130
2021 Q2	$3.72M	Hold	500,500	–	–	0.08%	124
2021 Q1	$4.05M	Hold	500,500	–	–	0.07%	126
2020 Q4	$4.55M	Hold	500,500	–	–	0.1%	111
2020 Q3	$5.54M	Hold	500,500	–	–	0.13%	95
2020 Q2	$3.72M	Hold	500,500	–	–	0.1%	113
2020 Q1	$3.08M	Hold	500,500	–	–	0.13%	91
2019 Q4	$2.51M	Sell	500,500 -400,000	-44%	-$2.54M	0.1%	91
2019 Q3	$6.78M	Hold	900,500	–	–	0.27%	62
2019 Q2	$10.4M	Sell	900,500 -46,919	-5%	-$683K	0.42%	49
2019 Q1	$13.7M	Buy	+947,419	New	+$13M	0.56%	41

Artal Group's KLDO Position: Q3 2022 in Review

Artal Group sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q3 2022, closing a stake of 500,500 shares — an estimated $31K sold.

Artal Group first reported a position in KLDO in Q1 2019 and held it in 14 quarters. The position peaked at $13.7M in Q1 2019. 0 funds tracked by Wall St. Rank hold KLDO as of Q3 2022.

Artal Group reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Artal Group sold 500,500 Kaleido Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $31K.
Artal Group first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2019 and held it in 14 quarters.
Artal Group's Kaleido Biosciences, Inc. Common Stock position peaked at $13.7M in Q1 2019.
0 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q3 2022.

Based on Artal Group's 13F filing for Q3 2022, filed 14 Nov 2022.